Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors
- PMID: 22271482
- DOI: 10.1200/JCO.2011.39.6390
Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors
Comment on
-
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.J Clin Oncol. 2012 Mar 10;30(8):777-82. doi: 10.1200/JCO.2011.36.1196. Epub 2012 Jan 23. J Clin Oncol. 2012. PMID: 22271473 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous